

**Fortis Healthcare Limited**

Tower-A, Unitech Business Park, Block-F,  
South City 1, Sector – 41, Gurgaon,  
Haryana – 122 001 (India)

Tel : 0124 492 1033

Fax : 0124 492 1041

**Emergency : 105010**

Email : [secretarial@fortishealthcare.com](mailto:secretarial@fortishealthcare.com)

Website : [www.fortishealthcare.com](http://www.fortishealthcare.com)

FHL/SEC/2024-25

August 9, 2024

**The National Stock Exchange of India Ltd.**  
Scrip Symbol: FORTIS

**BSE Limited**  
Scrip Code:532843

**Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations).**

Dear Sir/ Ma'am,

As previously informed by the Company in our Annual Report and our website in accordance with the requirements under Regulation 30A(2) of SEBI Listing Regulations, the Company and its material subsidiary, Agilus Diagnostics Limited (“**Agilus**”), had entered into a shareholders’ agreement dated June 12, 2012 (as amended from time to time) (“**Shareholders’ Agreement**”) with certain private equity investors in Agilus, including *inter alia* NYLIM Jacob Ballas India Fund III LLC (“**NJBIF**”), International Finance Corporation (“**IFC**”), and Resurgence PE Investments Limited (formerly known as Avigo PE Investments Limited) (“**Resurgence**”), collectively referred to as “**PE Investors**”. Under the terms of the Shareholders’ Agreement, the PE Investors have certain exit rights in respect of their shareholding in Agilus, including exit through exercise of put option by August 13, 2024, at fair market value in accordance with the processes and terms set out in the Shareholders’ Agreement.

In continuation to our earlier announcement dated August 8, 2024 and pursuant to Regulation 30 of the SEBI Listing Regulations, we would like to inform you that the Company on August 9, 2024 at 11:23 Hours (IST) and 17:39 Hours (IST) has also received a letter in respect of the exercise of put option right by Resurgence PE Investments Limited and International Finance Corporation for 6,310,315 and 5,970,149 equity shares equivalent to 8.05% and 7.61% equity stake respectively, held by them in Agilus.

The Company is in the process of assessing and taking all necessary steps as required to comply with its contractual obligations under the Shareholders’ Agreement, subject to applicable law.

This is for your information and records.

Thanking you,  
Yours sincerely,  
For **Fortis Healthcare Limited**

**Satyendra Chauhan**  
Company Secretary & Compliance Officer

---

**FORTIS HEALTHCARE LIMITED**

Regd. Office : Fortis Hospital, Sector 62, Phase – VIII, Mohali – 160062  
Tel : 0172-5096001, Fax : 0172-5096221, CIN : L85110PB1996PLC045933